{"name":"Alteogen, Inc.","slug":"alteogen-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"ALT-BB4","genericName":"ALT-BB4","slug":"alt-bb4","indication":"Other","status":"phase_1"},{"name":"ALT-L9","genericName":"ALT-L9","slug":"alt-l9","indication":"Other","status":"phase_1"},{"name":"ALT02","genericName":"ALT02","slug":"alt02","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ALT-BB4","genericName":"ALT-BB4","slug":"alt-bb4","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALT-L9","genericName":"ALT-L9","slug":"alt-l9","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ALT02","genericName":"ALT02","slug":"alt02","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQZ0VQRzVMS0xkRTFPX2pEclZ1b09rNE5JUHJxY0hOc19jNGpIY3c5eHc0U2lOV0ZWVEp3OG9PbUpSRzBzOU56UFduRUpPTVhGckhWcTdOb3pWVnZNYzBfUm9IUGRvWXN6aHR1YnFISzlBMld5QklsV0FWbjRaQWJxUmVqNFB3ZHRUTVcxZ3BSalBIUE1DZFE?oc=5","date":"2026-03-26","type":"deal","source":"The Pharma Letter","summary":"Alteogen strikes license agreement with Biogen - The Pharma Letter","headline":"Alteogen strikes license agreement with Biogen","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxNdDY3dVd4NE8yRFo3YTk2bVlWeFFSWmJaa0c4VjgtYXVVVDdYQXIyaUV6RnBTcWZhbExxSk9oT3JZU0F1NHFWNXZIQy0zejh0RDZRd0VFaWlYMFpEa1lGT0Y4Y3VxaG1vbE1mNHhqempKVzctMWpibFdMTzA2UHpIUWhJVkxSdWFWQkdEMTM0Ul92emNWNDZvNjV2VU5LcldLcWhCUkx2aGpBLS1MTk9EXzVhMXlYMkl3N2p5Y0FzNjhBZk1GdW81X2VLejNmZWcwWlVwcWRFWUQ?oc=5","date":"2026-03-26","type":"pipeline","source":"BioPharma APAC","summary":"Biogen Secures Exclusive Rights To Develop Subcutaneous Biologics Using Alteogen’s ALT B4 Platform - BioPharma APAC","headline":"Biogen Secures Exclusive Rights To Develop Subcutaneous Biologics Using Alteogen’s ALT B4 Platform","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPeFZMWDl2eTNIcHF5bTJvcVR2cUZfakpTVkhudWdMM1BmUVBGM1RkX3B4Q1doajUycDhoVW43ZnpmdzdVNGd2VjZRN1lSbWJiSnhOaUE4TEdnTUFYVndRMTg1RnhqWTBNUVZCSnVmeTB3aEloeXlKc09GYklsX2VhUtIBlAFBVV95cUxOdFYwM18yYmxDS2lSdnhFQk0zUGFXM0JIYlIwWXRJVFp5SW5qUTZjRWJNUlF6NnZsY3FoU2FyenVESEhfVzR1d2dfdzJYcUZ2dUFIRlBfcUp4Y091M2FtbTgyZFNqZ2lzSHZGVW5EeWU4azY1NXdiUUZKN0tXdElfZWVQLWVOMXdRRVlSMWhrSC1Cc2lB?oc=5","date":"2026-01-26","type":"pipeline","source":"Chosunbiz","summary":"K-bio stocks sway as South Korea confronts rumors and sharp sector volatility - CHOSUNBIZ - Chosunbiz","headline":"K-bio stocks sway as South Korea confronts rumors and sharp sector volatility - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOaXNUMFRRa3lVTkxEXzZVZjYzazlSejJPdTJ2NnJ3NHhQbG5wOTRKdWxwRzFkNVhkTXM2WkVLYlZ0WGllNFVGLVJFSVdzMzM3RFNORmdsRDFGeklOU1plUm9lM3l5bEZ3TzhuWWhZLUE2MWx1SGlXV1ZsNllLUW5tTWJTNHA4bmt2V3hzblRRdWdpNWJXYWtXQi1ZUUFCNjl0dXhXMHJsR0pkQTJicF9EUQ?oc=5","date":"2026-01-20","type":"pipeline","source":"Contract Pharma","summary":"Alteogen, Tesaro Agree to Develop Subcutaneous Form of Dostarlimab - Contract Pharma","headline":"Alteogen, Tesaro Agree to Develop Subcutaneous Form of Dostarlimab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPN3JRMXdtSXl3cTNoTlpSUUQyX0JCYVZHa1Jza3ptVUpLcUJ2TzZXSUowRWc5SnBkMlp6SzJtYjNYa19rc1pJS1JsSHBYTHJNdlNtbVZHb3VGdGNTSDRSNndRUXJabVBIc3AxOGN6ckpzUVJTekVqZmpzbVR0MFhVWGpWUWg2allob0xlZ1B6N0p1cXFVRFI2amhTWG82QURSa0htdFhMZFhBel9HaDlCMEQwSGhVVDNacV9pWE54QjB4LTJo?oc=5","date":"2025-09-18","type":"regulatory","source":"BioPharma APAC","summary":"EC Approves Alteogen’s EYLUXVI® as Eylea® Biosimilar for Major Ophthalmic Indications - BioPharma APAC","headline":"EC Approves Alteogen’s EYLUXVI® as Eylea® Biosimilar for Major Ophthalmic Indications","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOdERkODFuU0pDRVAzeDB0RTdwTEJTQnpGaHVWMDVGV0tVXzVYTmdFZ2RVTXFOa2pWUi1KWFhwWC05US1vQWpUVGFiSUo3V29fMnN1VElTOEp1ZXJxNmFfRlpHcUZwMnhscVJpMFBodW4tZF9SQ1BIc3FGd0gxcUF6bWlEQkF1MDlneXJucU5vVno0d2FYZExrSDVZYzlJUnlBMEE?oc=5","date":"2025-05-23","type":"pipeline","source":"BioWorld News","summary":"Alteogen merges two subsidiaries, forming Alteogen Biologics - BioWorld News","headline":"Alteogen merges two subsidiaries, forming Alteogen Biologics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9oNVpzQWZTY3IxY0RiT2lIOWtibXBMa0hXRFpoVndoZmN0TDdTME9CRFBNOG5tN0hVTGYxZXY3ZWozWjJVZVVoLWdKVHNLU0wzRFRSSzY3RlhHUnd3alI0NmZ4a2pVcDdDMF9FWXJR0gFyQVVfeXFMUGlUeXVQaG5jUGVrVkVkems0UmtCWV9pNmxSdWlUV0tiRXVNSnhnUXVZLWNabks1SFdoY0lpcWxzTEZFd3hWbktlbEZGclNiWXVTMTNpMGs3MHd0OWxldDI4cml6QjdZSmZCWjgtZ3ZZd19B?oc=5","date":"2025-05-22","type":"pipeline","source":"koreabiomed.com","summary":"Alteogen merges subsidiaries to launch Alteogen Biologics - koreabiomed.com","headline":"Alteogen merges subsidiaries to launch Alteogen Biologics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxON1BVUDMxRjgySzJkc3N0MmYtWkJSZlZKb1dDZ0xBMG5nMXh5b1JFWnRkV1ZlckRyWWliZ2FOaUF5cTBiM3VuNFFmazNSbzNrRzNIVndWNVdWcUNucjBsUU5DV1l5dDFGclJXR3luTElidkZXai11anJhRTNYcGxZWDlvWnFyTXcwQllOcko4TGVfOVNlS0xsU2xZcXl3eVhtSWZ1MlJuRVNZMU1mYTlHRw?oc=5","date":"2025-04-24","type":"pipeline","source":"Fierce Pharma","summary":"Halozyme sues Merck over subcutaneous Keytruda as licensing talks fall through - Fierce Pharma","headline":"Halozyme sues Merck over subcutaneous Keytruda as licensing talks fall through","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQdndOMl9EVU84ZGpyTklfSXNQLW5vSkxhLTVTNWJ3ekNISm4wWVJWazFKY3RfZzRhQTI5WGlrdDYwNnUzTHk2M2gtU01LUFNndGhuVl9yMkNYWVhnUkZuZTUydkpqZ29oUHBjZndDRDRKdXVjTlB5cGRYQjFVaDRxb2RBeHhIVnYwaDVxZTlQaEFrUUlKMkduSDdsNVM2QlA0RjV5VkZ4ZUt5d3NSUlFxQ2pNeW9OUQ?oc=5","date":"2025-03-21","type":"deal","source":"Fierce Pharma","summary":"Fierce Pharma Asia—AstraZeneca-Alteogen drug delivery deal; Taiho's ADC buyout; WuXi's rosy 2025 outlook - Fierce Pharma","headline":"Fierce Pharma Asia—AstraZeneca-Alteogen drug delivery deal; Taiho's ADC buyout; WuXi's rosy 2025 outlook","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxOT2JuSHFCSDR5MEp6LW9nRk15UUtPRzlRVUx1WWlRUU4wTmprM0dob1BuWkFBRkdrOG8zY21hQ0F1MHJQOWJ4cms1RkF0ekxBNEhUWmRTdTFfQllYQUFrazNPdkdGRkhRUVQ5Zk9SRHdwQjlSWElmWjIydlBMLXVXckptUXJzbnV2Umtrcm5TU2ptWjg4aThYVWpRNXhic2hSQUs5RGNYUHkyempMRktUODNwUVg1cXpXbUJVaW9fNjhtbzk0eVhjUm5wU1N5YjVCNk1qRkhn?oc=5","date":"2025-03-17","type":"pipeline","source":"Contract Pharma","summary":"AstraZeneca, Alteogen Enter Agreement for Subcutaneous Formulations of Oncology Assets - Contract Pharma","headline":"AstraZeneca, Alteogen Enter Agreement for Subcutaneous Formulations of Oncology Assets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE51TzBoM0RWT0pQbVFZQnFsNGhLWmRBQXRBOU54aXRzelhLWFBYel9CUWRLNTJkY3ZkY0hJUW54d3ZReFRtUnI5RzI4SXRDbzZYR1ZqT3hEZzZvWExZZDdyTkZfVDVmTmRhQjYtd3dn0gFyQVVfeXFMUDNndzBLNk1pclJacVlJM1BCMk5uR1B3Q0pkLS02Vm9rNjJOOHhvdVoxeXR1TjNhMkVad2owMHp0RGFfeVdWWmFlUjVPMUxYM0xiUm95UVc1aGRiODBVOEhyOUp4TXpEY2dwLVRZTmFmUS13?oc=5","date":"2024-11-08","type":"deal","source":"koreabiomed.com","summary":"Alteogen inks $300 mil. deal with Daiichi Sankyo to develop SC version of Enhertu - koreabiomed.com","headline":"Alteogen inks $300 mil. deal with Daiichi Sankyo to develop SC version of Enhertu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBtbFIteVJWTDQzMzd4WGdRTDNMbzRfam1QTG8xSmZLRm12dHdqZmhQVUR2MTEyY2hMc1kzcGFJaVFPT2dVcmVTMjNJMnhXSXdWWlNMVFpzbFZGOWwxZUNxYmV0UlBNQUNZN0N2cnlB?oc=5","date":"2022-12-30","type":"deal","source":"KED Global","summary":"S.Korea's Alteogen signs $145 million tech export deal with Swiss company - KED Global","headline":"S.Korea's Alteogen signs $145 million tech export deal with Swiss company","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":3},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}